Alemtuzumab News and Research

RSS

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.

21 Jul 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

26 Mar 2010

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme Corp., a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.

18 Feb 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Less expensive anti-rejection drug as effective as more expensive drug, says study

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

15 Oct 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Alemtuzumab News and Research

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genmab reports revenues of DKK 107M for first-quarter 2010

Genzyme to initiate $2 billion stock buyback

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genzyme announces fourth-quarter and full-year 2009 financial results

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

CAM314 randomized Phase 3 clinical trial results released

Less expensive anti-rejection drug as effective as more expensive drug, says study

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

New treatment strategies for multiple sclerosis

Monoclonal antibody cancer therapy

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Novel concept in chronic lymphoid leukemia treatment

Leukaemia drug may reverse multiple sclerosis brain damage

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News